The Impact of Acquired EGFR T790M Mutation and <i>EGFR</i> Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy.

We found a slightly higher incidence of the T790M mutation in patients treated with gefitinib or erlotinib than in those treated with afatinib (36 [40%] versus 15 [33%] subjects, respectively), although the difference did not reach statistical significance ( p = 0.449).

also in 111,027 other papers